FindTrial
Sign In

Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-505711-20-00
Acronym
1
Enrollment
4
Registered
2023-08-11
Start date
2023-08-13
Completion date
2024-01-23
Last updated
2023-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic rhinosinusitis with nasal polyps

Brief summary

mean change of NPS and SNOT-22 scores from baseline to week 16

Detailed description

mean change from baseline to week 16 in IL-17 associated inflammatory markers

Interventions

DRUGCosentyx 150 mg solution for injection in pre-filled syringe

Sponsors

Tartu University Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
mean change of NPS and SNOT-22 scores from baseline to week 16—

Secondary

MeasureTime frame
mean change from baseline to week 16 in IL-17 associated inflammatory markers—

Countries

Estonia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026